 OncLive | Dutch Researcher Focuses on Fc Signaling in Targeting CD20 - OncLive OncLive Building on the success achieved with rituximab (RTX), other anti-CD20 monoclonal antibodies (mAbs) are being investigated. The fully human anti-CD20 mAb ofatumumab was approved by FDA in October 2009 for chronic lymphocytic leukemia (CLL). |
